Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, placebo-controlled, double-blind study of 2LHERP in recurrent orofacial herpes
2019-001085-15Phase 4Active
- Sponsor
- Labo'Life
- Start
- Aug 2019
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in herpes simplex (HSV) comparing 2LHERP with Placebo (2 arms). Primary endpoint: Reduction in number of recurrences at 12 months. Started Aug 2019; status: active.
02
Drugs
2LHERP
03
Conditions
herpes simplex (HSV)
Beyond the preview
Go deeper on 2019-001085-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001085-15.